BioNTech SE Form 6-K Summary (Nov 2025)

BioNTech SE filed this Form 6-K on November 3, 2025, reporting on the third quarter of 2025.

• Critical Disclosure: The filing incorporates by reference Exhibit 99.1, which contains the complete interim condensed consolidated financial statements and operating review for the three and nine months ended September 30, 2025.
• Financial details, strategic updates, and guidance are located in Exhibit 99.1.
• The report was certified by CFO Ramón Zapata-Gomez and COO Dr. Sierk Poetting.

Investors must review Exhibit 99.1 for *